Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 7/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.55 |
| ▸ | KAT2B | Q92831 | 5/20 | 0.53 |
| ▸ | CCR2 | P41597 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.47 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12846293 | 0.93 | MCHR1 (0.56) | ROCK2ROCK1CCR2MCHR1 | |
| SCHEMBL12846004 | 0.84 | ACHE (0.59) | ROCK2ROCK1 | |
| SCHEMBL4425040 | 0.79 | ROCK2 (0.71) | ROCK2ROCK1CCR2MCHR1 | |
| SCHEMBL32679933 | 0.79 | KAT2B (0.54) | ROCK2ROCK1KAT2BCCR2JAK2 | |
| SCHEMBL14155727 | 0.79 | KAT2B (0.56) | ROCK2ROCK1KAT2BCCR2JAK2 | |
| SCHEMBL13153524 | 0.78 | KDM4E (0.60) | ROCK2ROCK1JAK2 | |
| SCHEMBL5870954 | 0.77 | ROCK2 (0.65) | ROCK2ROCK1KAT2BCCR2 | |
| SCHEMBL27171797 | 0.76 | KAT2B (0.55) | ROCK2ROCK1KAT2BCCR2EHMT2 | |
| SCHEMBL12845958 | 0.76 | ACHE (0.54) | ROCK2ROCK1MCHR1 | |
| SCHEMBL28756754 | 0.76 | DRD2 (0.57) | ROCK2ROCK1KAT2BCCR2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150072972-A1 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-12 | — | — | US | disclosed |
| US-8946221-B2 | Phthalazine derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2015-02-03 | — | — | US | disclosed |
| US-20110065684-A1 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS | MEVELLEC LAURENCE ANNE | 2011-03-17 | — | — | US | disclosed |
| US-7803795-B2 | Phthalazine derivatives as parp inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-28 | — | — | US | disclosed |
| US-7803795-B2 | Phthalazine derivatives as parp inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072972-A1 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP11 | ROCK2 1136/4885ROCK1 1347/4885KAT2B 418/4885 |
| US-20110065684-A1 | PHTHALAZINE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP11 | ROCK2 1136/4885ROCK1 1347/4885KAT2B 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.